IDEAS home Printed from https://ideas.repec.org/r/eee/jhecon/v24y2005i1p1-31.html
   My bibliography  Save this item

Do new prescription drugs pay for themselves?: The case of second-generation antipsychotics

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Anne Penneau & Damien Bricard & Zeynep Or, 2019. "Améliorer la prise en charge sanitaire et sociale des personnes âgées : impact des plans personnalisés de santé sur les parcours de soins," Working Papers DT81, IRDES institut for research and information in health economics, revised Jul 2019.
  2. Lazuka, Volha, 2021. "Heterogeneous Returns to Medical Innovations," Lund Papers in Economic History 225, Lund University, Department of Economic History.
  3. Basu, Anirban & Jena, Anupam B. & Philipson, Tomas J., 2011. "The impact of comparative effectiveness research on health and health care spending," Journal of Health Economics, Elsevier, vol. 30(4), pages 695-706, July.
  4. Markussen, Simen & Røed, Knut, 2014. "The impacts of vocational rehabilitation," Labour Economics, Elsevier, vol. 31(C), pages 1-13.
  5. Dalsgaard, Søren & Nielsen, Helena Skyt & Simonsen, Marianne, 2014. "Consequences of ADHD medication use for children's outcomes," Journal of Health Economics, Elsevier, vol. 37(C), pages 137-151.
  6. Schreiner, Ragnhild C., 2019. "Unemployed or Disabled? Disability Screening and Labor Market Outcomes of Youths," Memorandum 5/2019, Oslo University, Department of Economics.
  7. Mayank Aggarwal & Anindya S. Chakrabarti & Chirantan Chatterjee, 2023. "Movies, stigma and choice: Evidence from the pharmaceutical industry," Health Economics, John Wiley & Sons, Ltd., vol. 32(5), pages 1019-1039, May.
  8. Rema Hanna & Esther Duflo & Michael Greenstone, 2016. "Up in Smoke: The Influence of Household Behavior on the Long-Run Impact of Improved Cooking Stoves," American Economic Journal: Economic Policy, American Economic Association, vol. 8(1), pages 80-114, February.
  9. Ying Qiu & Alex Fu & Gordon Liu & Dale Christensen, 2010. "Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a medicaid programme," Applied Health Economics and Health Policy, Springer, vol. 8(3), pages 167-177, May.
  10. Chorniy, Anna, 2016. "Sex, Drugs, and ADHD: The Effects of ADHD Pharmacological Treatment on Teens' Risky Behaviors," VfS Annual Conference 2016 (Augsburg): Demographic Change 145766, Verein für Socialpolitik / German Economic Association.
  11. Ya‐Ming Liu & Chee‐Ruey Hsieh, 2012. "New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan," Health Economics, John Wiley & Sons, Ltd., vol. 21(5), pages 496-513, May.
  12. Margaret K. Kyle, 2019. "The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals," NBER Chapters, in: Innovation Policy and the Economy, Volume 20, pages 95-123, National Bureau of Economic Research, Inc.
  13. Soohyung Lee & Keunkwan Ryu, 2012. "Plastic Surgery: Investment in Human Capital or Consumption?," Journal of Human Capital, University of Chicago Press, vol. 6(3), pages 224-250.
  14. Abe Dunn & Eli Liebman & Adam Hale Shapiro, 2015. "Implications of Utilization Shifts on Medical‐care Price Measurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(5), pages 539-557, May.
  15. Muzhe Yang & Hsien-Ming Lien & Shin-Yi Chou, 2014. "Is There A Physician Peer Effect? Evidence From New Drug Prescriptions," Economic Inquiry, Western Economic Association International, vol. 52(1), pages 116-137, January.
  16. Rexford E. Santerre, 2011. "National and International Tests of the New Drug Cost Offset Theory," Southern Economic Journal, John Wiley & Sons, vol. 77(4), pages 1033-1043, April.
  17. Rehwald, Kai & Rosholm, Michael & Rouland, Bénédicte, 2018. "Labour market effects of activating sick-listed workers," Labour Economics, Elsevier, vol. 53(C), pages 15-32.
  18. Markussen, Simen & Mykletun, Arnstein & Røed, Knut, 2012. "The case for presenteeism — Evidence from Norway's sickness insurance program," Journal of Public Economics, Elsevier, vol. 96(11), pages 959-972.
  19. Duggan Mark G & Evans William N, 2008. "Estimating the Impact of Medical Innovation: A Case Study of HIV Antiretroviral Treatments," Forum for Health Economics & Policy, De Gruyter, vol. 11(2), pages 1-39, January.
  20. Anna A. Levine Taub & Anton Kolotilin & Robert S. Gibbons & Ernst R. Berndt, 2011. "The Diversity of Concentrated Prescribing Behavior: An Application to Antipsychotics," NBER Working Papers 16823, National Bureau of Economic Research, Inc.
  21. Kools, Lieke & Koning, Pierre, 2019. "Graded return-to-work as a stepping stone to full work resumption," Journal of Health Economics, Elsevier, vol. 65(C), pages 189-209.
  22. Craig L. Garthwaite, 2012. "The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors," American Economic Journal: Applied Economics, American Economic Association, vol. 4(3), pages 116-137, July.
  23. Omar Galárraga & David S. Salkever & Judith A. Cook & Stephen J. Gange, 2010. "An instrumental variables evaluation of the effect of antidepressant use on employment among HIV‐infected women using antiretroviral therapy in the United States: 1996–2004," Health Economics, John Wiley & Sons, Ltd., vol. 19(2), pages 173-188, February.
  24. Glazer, Jacob & McGuire, Thomas G., 2012. "A welfare measure of “offset effects” in health insurance," Journal of Public Economics, Elsevier, vol. 96(5), pages 520-523.
  25. Javitt, Jonathan C. & Rebitzer, James B. & Reisman, Lonny, 2008. "Information technology and medical missteps: Evidence from a randomized trial," Journal of Health Economics, Elsevier, vol. 27(3), pages 585-602, May.
  26. Markussen, Simen & Røed, Knut & Røgeberg, Ole J., 2013. "The Changing of the Guards: Can Physicians Contain Social Insurance Costs?," IZA Discussion Papers 7122, Institute of Labor Economics (IZA).
  27. Ludwig, Jens & Marcotte, Dave E. & Norberg, Karen, 2009. "Anti-depressants and suicide," Journal of Health Economics, Elsevier, vol. 28(3), pages 659-676, May.
  28. Richard G. Frank & Thomas G. McGuire & Sharon-Lise Normand, 2006. "Cost-Offsets of New Medications for Treatment of Schizophrenia," NBER Working Papers 12643, National Bureau of Economic Research, Inc.
  29. Gaynor Martin & Li Jian & Vogt William B, 2007. "Substitution, Spending Offsets, and Prescription Drug Benefit Design," Forum for Health Economics & Policy, De Gruyter, vol. 10(2), pages 1-33, July.
  30. James B. Rebitzer & Mari Rege & Christopher Shepard, 2008. "Influence, information overload, and information technology in health care," Advances in Health Economics and Health Services Research, in: Beyond Health Insurance: Public Policy to Improve Health, pages 43-69, Emerald Group Publishing Limited.
  31. Dimitrova, V.; & Sameen, H.;, 2022. "Static regulation and technological change: Prescribing cost-effective treatments under financial constraints in the English NHS," Health, Econometrics and Data Group (HEDG) Working Papers 22/15, HEDG, c/o Department of Economics, University of York.
  32. Chorniy, Anna & Kitashima, Leah, 2016. "Sex, drugs, and ADHD: The effects of ADHD pharmacological treatment on teens' risky behaviors," Labour Economics, Elsevier, vol. 43(C), pages 87-105.
  33. Mark Duggan & Fiona Scott Morton, 2010. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization," American Economic Review, American Economic Association, vol. 100(1), pages 590-607, March.
  34. Volha Lazuka, 2022. "Household and individual economic responses to different health shocks: The role of medical innovations," Papers 2206.03306, arXiv.org, revised Nov 2022.
  35. Aizcorbe, Ana & Nestoriak, Nicole, 2011. "Changing mix of medical care services: Stylized facts and implications for price indexes," Journal of Health Economics, Elsevier, vol. 30(3), pages 568-574, May.
  36. Berndt, Ernst R. & Gibbons, Robert S. & Kolotilin, Anton & Taub, Anna Levine, 2015. "The heterogeneity of concentrated prescribing behavior: Theory and evidence from antipsychotics," Journal of Health Economics, Elsevier, vol. 40(C), pages 26-39.
  37. Markussen, Simen & Røed, Knut & Røgeberg, Ole, 2013. "The changing of the guards," Journal of Health Economics, Elsevier, vol. 32(6), pages 1230-1239.
  38. Mark Duggan & Fiona M. Scott Morton, 2006. "The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 121(1), pages 1-30.
  39. Abdülkadi̇r Ci̇van & Bülent Köksal, 2010. "The effect of newer drugs on health spending: do they really increase the costs?," Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 581-595, May.
  40. Law, Michael R. & Grépin, Karen A., 2010. "Is newer always better? Re-evaluating the benefits of newer pharmaceuticals," Journal of Health Economics, Elsevier, vol. 29(5), pages 743-750, September.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.